NTRA - Natera and BGI Genomics launch Signatera Assay in China

Natera ([[NTRA]] +0.4%) and BGI Genomics announces the launch of the BGI/Natera Signatera Assay in China.The company's Signatera assay has been utilized in numerous clinical studies across non-small cell lung, bladder, breast and colorectal cancers, to identify molecular residual disease ((MRD)) up to two years earlier than standard imaging.Natera had announced that the Centers for Medicare & Medicaid Services ((CMS)) granted advanced diagnostic laboratory test  ((ADLT)) status for the Signatera MRD test, earlier this month.

For further details see:

Natera and BGI Genomics launch Signatera Assay in China